The Dikman Company, a commercial/industrial real estate services firm announced today M2Gen’s move to a larger Tampa location at 4904 Eisenhower Blvd., Presidents Plaza II, Tampa, FL 33634. Bob Dikman of The Dikman Company represented M2Gen, securing the 17,091 square foot sublease.
“M2Gen continues to grow rapidly, requiring the significant expansion of the number of information technology and bioinformatics employees, creating the need for larger space,” said Joseph Smith, senior vice president and chief financial officer at M2Gen. “When working with Bob and The Dikman Company, we saw their commitment to understanding our situation and their attention to detail. The location they found for our new corporate headquarters close to Tampa International Airport and adjacent counties, allows M2Gen to attract and retain high quality personnel.”
“Commercial office space in the Tampa region is tight right now, but understanding the market helped us find the right location with quality amenities quickly,” said Bob Dikman, chairman and chief executive officer, The Dikman Company. “It was a pleasure to work with the M2Gen team. We pride ourselves on the best customer service for our clients, and we are pleased that we could secure this new location for M2Gen.”
About The Dikman Company
The Dikman Company is a Commercial/Industrial Real Estate firm that has been providing clients throughout Florida with a full range of services since 1983. The company offers extensive industry experience and strong market knowledge to ensure commercial real estate transactions are successfully executed and client goals are met and exceeded. Commercial real estate services include: development, sales, leasing, property management, tenant representation, investment counseling and asset analysis. For more information, visit www.dikman.com.
M2Gen® is a health informatics solutions company focused on accelerating the discovery and development of precision medicine and serves as the operational arm of the Oncology Research Information Exchange Network (ORIEN®), an alliance of the nation’s leading cancer centers. These centers enroll patients onto the Total Cancer Care® (TCC) Protocol, the world’s largest prospective study in cancer, and share data from this study with each other and the biopharmaceutical companies via M2Gen. By leveraging data science expertise, M2Gen is helping biopharmaceutical companies decrease R&D costs, run more effective clinical trials and accelerate drug development timelines- each for the benefit of patients. For more information visit www.m2gen.com.